vs
GLOBUS MEDICAL INC（GMED）与WESTERN ALLIANCE BANCORPORATION（WAL）财务数据对比。点击上方公司名可切换其他公司
WESTERN ALLIANCE BANCORPORATION的季度营收约是GLOBUS MEDICAL INC的1.2倍（$1.0B vs $826.4M），WESTERN ALLIANCE BANCORPORATION净利率更高（18.6% vs 17.0%，领先1.6%），WESTERN ALLIANCE BANCORPORATION同比增速更快（31.0% vs 25.7%），过去两年GLOBUS MEDICAL INC的营收复合增速更高（16.7% vs 14.9%）
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
Western Alliance Bancorporation是总部位于美国菲尼克斯的区域性银行控股公司，长期深耕美国本土区域金融服务市场，目前已跻身美国最大银行行列，在福布斯发布的美国最佳银行榜单中排名第97位。
GMED vs WAL — 直观对比
营收规模更大
WAL
是对方的1.2倍
$826.4M
营收增速更快
WAL
高出5.2%
25.7%
净利率更高
WAL
高出1.6%
17.0%
两年增速更快
GMED
近两年复合增速
14.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $826.4M | $1.0B |
| 净利润 | $140.6M | $189.2M |
| 毛利率 | 68.4% | — |
| 营业利润率 | 20.5% | — |
| 净利率 | 17.0% | 18.6% |
| 营收同比 | 25.7% | 31.0% |
| 净利润同比 | 430.4% | -5.0% |
| 每股收益（稀释后） | $1.01 | $1.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMEDWAL
| Q1 26 | — | $1.0B | ||
| Q4 25 | $826.4M | $980.9M | ||
| Q3 25 | $769.0M | $938.2M | ||
| Q2 25 | $745.3M | $845.9M | ||
| Q1 25 | $598.1M | $778.0M | ||
| Q4 24 | $657.3M | $838.4M | ||
| Q3 24 | $625.7M | $823.1M | ||
| Q2 24 | $629.7M | $771.8M |
净利润GMEDWAL
| Q1 26 | — | $189.2M | ||
| Q4 25 | $140.6M | $286.1M | ||
| Q3 25 | $119.0M | $253.4M | ||
| Q2 25 | $202.8M | $230.4M | ||
| Q1 25 | $75.5M | $199.1M | ||
| Q4 24 | $26.5M | $216.9M | ||
| Q3 24 | $51.8M | $199.8M | ||
| Q2 24 | $31.8M | $193.6M |
毛利率GMEDWAL
| Q1 26 | — | — | ||
| Q4 25 | 68.4% | — | ||
| Q3 25 | 67.2% | — | ||
| Q2 25 | 66.6% | — | ||
| Q1 25 | 67.3% | — | ||
| Q4 24 | 59.9% | — | ||
| Q3 24 | 56.8% | — | ||
| Q2 24 | 58.7% | — |
营业利润率GMEDWAL
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | 36.3% | ||
| Q3 25 | 17.9% | 33.4% | ||
| Q2 25 | 10.2% | 34.4% | ||
| Q1 25 | 16.2% | 31.7% | ||
| Q4 24 | 9.2% | 30.9% | ||
| Q3 24 | 7.7% | 30.6% | ||
| Q2 24 | 7.9% | 32.1% |
净利率GMEDWAL
| Q1 26 | — | 18.6% | ||
| Q4 25 | 17.0% | 29.2% | ||
| Q3 25 | 15.5% | 27.0% | ||
| Q2 25 | 27.2% | 27.2% | ||
| Q1 25 | 12.6% | 25.6% | ||
| Q4 24 | 4.0% | 25.9% | ||
| Q3 24 | 8.3% | 24.3% | ||
| Q2 24 | 5.0% | 25.1% |
每股收益（稀释后）GMEDWAL
| Q1 26 | — | $1.65 | ||
| Q4 25 | $1.01 | $2.59 | ||
| Q3 25 | $0.88 | $2.28 | ||
| Q2 25 | $1.49 | $2.07 | ||
| Q1 25 | $0.54 | $1.79 | ||
| Q4 24 | $0.19 | $1.94 | ||
| Q3 24 | $0.38 | $1.80 | ||
| Q2 24 | $0.23 | $1.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $557.2M | — |
| 总债务越低越好 | — | $4.3B |
| 股东权益账面价值 | $4.6B | $7.9B |
| 总资产 | $5.3B | $98.9B |
| 负债/权益比越低杠杆越低 | — | 0.54× |
8季度趋势，按日历期对齐
现金及短期投资GMEDWAL
| Q1 26 | — | — | ||
| Q4 25 | $557.2M | — | ||
| Q3 25 | $18.8M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $890.1M | — | ||
| Q3 24 | $71.9M | — | ||
| Q2 24 | $82.5M | — |
总债务GMEDWAL
| Q1 26 | — | $4.3B | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $2.9B | ||
| Q2 25 | — | $2.9B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $436.0M |
股东权益GMEDWAL
| Q1 26 | — | $7.9B | ||
| Q4 25 | $4.6B | $7.7B | ||
| Q3 25 | $4.4B | $7.4B | ||
| Q2 25 | $4.3B | $7.1B | ||
| Q1 25 | $4.1B | $6.9B | ||
| Q4 24 | $4.2B | $6.7B | ||
| Q3 24 | $4.1B | $6.7B | ||
| Q2 24 | $4.0B | $6.3B |
总资产GMEDWAL
| Q1 26 | — | $98.9B | ||
| Q4 25 | $5.3B | $92.8B | ||
| Q3 25 | $5.1B | $91.0B | ||
| Q2 25 | $5.0B | $86.7B | ||
| Q1 25 | $4.7B | $83.0B | ||
| Q4 24 | $5.3B | $80.9B | ||
| Q3 24 | $5.1B | $80.1B | ||
| Q2 24 | $5.0B | $80.6B |
负债/权益比GMEDWAL
| Q1 26 | — | 0.54× | ||
| Q4 25 | — | 0.18× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.23× | ||
| Q4 24 | — | 0.36× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $248.6M | — |
| 自由现金流经营现金流 - 资本支出 | $202.4M | — |
| 自由现金流率自由现金流/营收 | 24.5% | — |
| 资本支出强度资本支出/营收 | 5.6% | — |
| 现金转化率经营现金流/净利润 | 1.77× | — |
| 过去12个月自由现金流最近4个季度 | $588.8M | — |
8季度趋势，按日历期对齐
经营现金流GMEDWAL
| Q1 26 | — | — | ||
| Q4 25 | $248.6M | $-2.7B | ||
| Q3 25 | $249.7M | $-597.4M | ||
| Q2 25 | $77.9M | $-357.7M | ||
| Q1 25 | $177.3M | $-1.7B | ||
| Q4 24 | $210.3M | $-2.7B | ||
| Q3 24 | $203.7M | $-1.1B | ||
| Q2 24 | $54.3M | $-745.8M |
自由现金流GMEDWAL
| Q1 26 | — | — | ||
| Q4 25 | $202.4M | — | ||
| Q3 25 | $213.9M | — | ||
| Q2 25 | $31.3M | — | ||
| Q1 25 | $141.2M | — | ||
| Q4 24 | $193.2M | — | ||
| Q3 24 | $161.7M | — | ||
| Q2 24 | $26.5M | — |
自由现金流率GMEDWAL
| Q1 26 | — | — | ||
| Q4 25 | 24.5% | — | ||
| Q3 25 | 27.8% | — | ||
| Q2 25 | 4.2% | — | ||
| Q1 25 | 23.6% | — | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 25.8% | — | ||
| Q2 24 | 4.2% | — |
资本支出强度GMEDWAL
| Q1 26 | — | — | ||
| Q4 25 | 5.6% | — | ||
| Q3 25 | 4.7% | — | ||
| Q2 25 | 6.2% | — | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | 4.4% | — |
现金转化率GMEDWAL
| Q1 26 | — | — | ||
| Q4 25 | 1.77× | -9.36× | ||
| Q3 25 | 2.10× | -2.36× | ||
| Q2 25 | 0.38× | -1.55× | ||
| Q1 25 | 2.35× | -8.31× | ||
| Q4 24 | 7.94× | -12.64× | ||
| Q3 24 | 3.93× | -5.35× | ||
| Q2 24 | 1.71× | -3.85× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
WAL
暂无分部数据
